Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Diabetologia
Published in: Diabetologia 9/2006

01-09-2006 | Letter

Sulfonylurea treatment outweighs insulin therapy in short-term metabolic control of patients with permanent neonatal diabetes mellitus due to activating mutations of the KCNJ11 (KIR6.2) gene

Authors: G. Tonini, C. Bizzarri, R. Bonfanti, M. Vanelli, F. Cerutti, E. Faleschini, F. Meschi, F. Prisco, E. Ciacco, M. Cappa, C. Torelli, V. Cauvin, S. Tumini, D. Iafusco, F. Barbetti, Early-Onset Diabetes Study Group of the Italian Society of Paediatric Endocrinology and Diabetology

Published in: Diabetologia | Issue 9/2006

Login to get access

Excerpt

To the Editor, …
Literature
1.
Gloyn AL, Pearson ER, Antcliff JF et al (2004) Activating mutations in the ATP-sensitive potassium channel subunit Kir6.2 gene are associated with permanent neonatal diabetes. N Engl J Med 350:1838–1849PubMedCrossRef
2.
Hattersley AT, Ashcroft FM (2005) Activating mutations in Kir6.2 and neonatal diabetes. New clinical syndromes, new scientific insights, and new therapy. Diabetes 54:2503–2513PubMedCrossRef
3.
Gloyn AL, Reimann F, Girard C et al (2005) Relapsing diabetes can result from moderately activating mutations in KCNJ11. Hum Mol Genet 14:925–934PubMedCrossRef
4.
Colombo C, Del Vecchio M, Zecchino C, Faienza MF, Cavallo L, Barbetti F (2005) Transient neonatal diabetes mellitus is associated with a recurrent (R201H) KCNJ11 (KIR6.2) mutation. Diabetologia 48:2439–2441PubMedCrossRef
5.
Sagen J, Raeder H, Hathout E et al (2004) Permanent neonatal diabetes due to mutations in KCNJ11 encoding Kir6.2. Patient characteristics and initial response to sulfonylurea therapy. Diabetes 53:2713–2718PubMedCrossRef
6.
Zung A, Glaser B, Nimri R, Zadik Z (2004) Glibenclamide treatment in permanent neonatal diabetes mellitus due to an activating mutation in Kir6.2. J Clin Endocrinol Metab 89:5504–5507PubMedCrossRef
7.
Kupla T, Edghill EL, Nazim J et al (2005) The identification of a R201H mutation in KCNJ11, which encodes Kir6.2, and successful transfer to sustained-release suplhonylurea therapy in a subject with neonatal diabetes: evidence for heterogeneity of beta cell function among carriers of the R201H mutation. Diabetologia 48:1029–1031CrossRef
8.
Codner E, Flanagan S, Ellard S, Hernan G, Hattersley AT (2005) High dose glibenclamide can replace insulin therapy despite transitory diarrhea in early-onset diabetes caused by a novel R201L Kir6.2 mutation. Diabetes Care 28:758–759PubMedCrossRef
9.
Massa O, Iafusco D, D’Amato E et al (2005) KCNJ11 activating mutations in Italian patients with permanent neonatal diabetes. Hum Mutat 25:22–27PubMedCrossRef
10.
Koster JC, Remedi MS, Dao C, Nichols CG (2005) ATP and sulfonylurea sensitivity of mutant ATP-sensitive K+ channels in neonatal diabetes. Diabetes 54:2645–2654PubMedCrossRef
Metadata
Title
Sulfonylurea treatment outweighs insulin therapy in short-term metabolic control of patients with permanent neonatal diabetes mellitus due to activating mutations of the KCNJ11 (KIR6.2) gene
Authors
G. Tonini
C. Bizzarri
R. Bonfanti
M. Vanelli
F. Cerutti
E. Faleschini
F. Meschi
F. Prisco
E. Ciacco
M. Cappa
C. Torelli
V. Cauvin
S. Tumini
D. Iafusco
F. Barbetti
Early-Onset Diabetes Study Group of the Italian Society of Paediatric Endocrinology and Diabetology
Publication date
01-09-2006
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 9/2006
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-006-0329-x

Other articles of this Issue 9/2006

Diabetologia 9/2006 Go to the issue

Research Letter

Increased syndecan-1 in serum is related to early nephropathy in type 1 diabetes mellitus patients

Article

Within-patient variation of the pharmacokinetics of subcutaneously injected biphasic insulin aspart as assessed by compartmental modelling

Article

Leptin and incident type 2 diabetes: risk or protection?

Research Letter

Plasma concentrations of vascular endothelial growth factor are associated with peripheral oedema in patients treated with thiazolidinedione

Article

Restoration of normal glucose tolerance in severely obese patients after bilio-pancreatic diversion: role of insulin sensitivity and beta cell function

Article

Dysregulation of muscle fatty acid metabolism in type 2 diabetes is independent of malonyl-CoA
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits